Voyager Therapeutics Names Robin Swartz President; CEO Transition Set for Q1 2027; Shares Fall 7%

Voyager Therapeutics Inc. (VYGR) said Wednesday that Robin Swartz has been appointed president, effective October 20, 2026, and is expected to succeed Alfred W. Sandrock Jr. as CEO in the first quarter of 2027. Shares fell 7.08% to $2.03. The CEO transition is expected to follow receipt of initial acute safety data from a trial of VY1706, Voyager's investigational tau-silencing gene therapy for adults with early Alzheimer's disease. The company expects that data in the first quarter of 2027, depending on patient enrollment. Sandrock will remain CEO through the milestone and then continue on the board. Swartz, currently chief business officer and chief operating officer, joined Voyager in 2021 and has overseen clinical development, finance, legal and portfolio strategy. Before Voyager, she spent 26 years at Genzyme Corporation and Sanofi Genzyme in leadership roles across commercial operations, development, strategy and finance.